AbCellera Biologics
ABCL
ABCL
170 hedge funds and large institutions have $809M invested in AbCellera Biologics in 2023 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 42 increasing their positions, 50 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
17% less capital invested
Capital invested by funds: $980M → $809M (-$171M)
21% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 48
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Holders
170
Holding in Top 10
4
Calls
$7.78M
Puts
$2.94M
Top Buyers
| 1 | +$42.2M | |
| 2 | +$38.8M | |
| 3 | +$26.5M | |
| 4 |
Millennium Management
New York
|
+$13.3M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$11.6M |
Top Sellers
| 1 | -$66.2M | |
| 2 | -$31M | |
| 3 | -$20.3M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.4M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$10.2M |